Pinsent Masons advises the UK government on purchase of further 60m doses of Covid-19 vaccines

10 May 2021 | 09:36 am |

Multinational law firm Pinsent Masons has successfully advised the UK government on an agreement to purchase an additional 60m doses of the Pfizer BioNTech Covid-19 vaccine for the autumn revaccination programme.

The team at Pinsent Masons was led by Life Sciences transactions partner Allistair Booth and included Andy Cornforth, Niki Ruprai, Robert Sherville-Payne and Aaron Hope. 

Commenting on the agreement, Allistair Booth, lead partner at Pinsent Masons said:

"This is an important agreement. Access to 60m doses of that vaccine in time for an autumn revaccination programme will hopefully play a key role in protecting the NHS and the most vulnerable people of the UK.


"We are proud to have worked with the UK government on securing this agreement for such an important vaccine at such a crucial time".  

Latest press releases

Show me all press releases

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.

Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising

Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.

Pinsent Masons advises Alveo on its sale to Symphony Technology Group

Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises UMS Consulting on its acquisition by Expleo

Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.

Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.

Pinsent Masons launches parallel trade monitoring platform for life sciences sector

Multinational law firm Pinsent Masons launches innovative online tool to help life sciences organisations grappling with parallel trade management.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.